Today, Kite expanded its research and development deal--or CRADA--with some key researchers at the National Cancer Institute to cover additional programs and targeting tools needed to beef up its pipeline during a critical stage of development for this hotly competitive niche in the cancer arena.
Welcome to the latest edition of our weekly EuroBiotech Report. Neil Woodford revealed the board of his new fund this week and hinted at his strategy in the process. With three-quarters of the board having biotech credentials and the same proportion being intrinsically linked to "golden triangle" commercialization business Imperial Innovations, Woodford looks set to go all in on south east England's academic hotspots. The U.K. government is set to further bolster the credentials of the region by setting up an international dementia institute within 5 years and lending its support to a dementia R&D investment fund. Prexton Therapeutics grabbed a slice of the CNS funding that is available today, raising €8.7 million ($9.9 million) to take its Parkinson's disease candidate into the clinic. The biotech was set up by ex-Merck Serono staffers amid the shuttering of the German firm's Geneva R&D center. Chiesi became the first company to win approval for a stem-cell therapy in the West. Ipsen handed over €6 million for the option to buy Canbex Therapeutics once it gets a look at Phase IIa data on a spasticity treatment. And more. Read the full report >>
Welcome to FierceBiotech Radio, a podcast in which we'll chat with industry experts, newsmakers and veterans on issues affecting the business of biopharma. The idea is to replicate the off-the-cuff encounters normally confined to insider confabs, avoiding the dullness of hyperscripted earnings calls and technical webinars. Read more and listen >>
Sanofi has received the FDA marketing approval it badly needed for the long-acting basal insulin Toujeo, a product designed to preserve its multibillion-dollar franchise revenue from Lantus. But at least one prominent analyst was quick to question its impact, noting that the label will offer little compelling reason for a switch from the established market blockbuster. And that is likely to set up some early price discounting that will further roil the huge and growing diabetes market for all the key players. Read more >>
In his first public move since being ousted as Sanofi CEO, Chris Viehbacher has joined the board of directors at Boston startup factory PureTech Ventures. Read more >>
POPULAR COMMENT THREADS
Shanghai is becoming just as important to a company's future as San Francisco or London or New York. And we want to cover that transformation. Read more >>
The FDA has accepted Bristol-Myers Squibb's application to get its star oncology treatment approved for lung cancer, setting up a speedy approval and putting the company first in line among drug developers at work in a blockbuster field.
For more than a year now, NEA general partner David Mott has helmed Mersana Therapeutics, a Cambridge, MA-based biotech that has been working on next-gen antibody-drug conjugates. But this morning he's handing the reins over to longtime biotech vet Anna Protopapas (while remaining chairman) after organizing a $35 million B round that will be announced later this morning.
A week after first raising the flag on their newborn biotech, a pair of entrepreneurs unhatched a deal today to take down a drug program that has been gathering dust on Amgen's R&D shelves for the past 7 years and test it as a new treatment for celiac disease.
Memorial Sloan Kettering Cancer Center picked up the FDA's coveted breakthrough-therapy designation for a promising T cell therapy, working with partner Atara Biotherapeutics to get it on the market for patients with complications tied to bone marrow transplants.
Cleveland-based Athersys is pocketing a $10 million upfront payment from Chugai in exchange for licensing rights to the biotech's stem cell treatment for repairing stroke damage. The Japanese pharma company, which has close relations with Roche, also stands to earn up to $45 million in development and regulatory milestones with another $150 million in sales milestones.
From Our Sister Sites
In an effort to expand into life sciences, Tokyo-based JSR, a materials producer with 5,500 employees, has announced its intention to acquire Durham, NC-based contract manufacturer KBI Biopharma.
G&W Laboratories, which bought an Actavis facility in North Carolina last summer, is now taking over a Teva Pharmaceutical Industries facility in Pennsylvania that was on the cusp of closing.